{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-036268","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2026-08-06T12:20:41+00:00","discovered_at":"2026-08-06T12:25:04.328021+00:00","generated_at":"2026-08-06T12:25:18.515013+00:00","sec_items":["1.01","5.03","2.01","3.02","3.03","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ensysce acquires Cy Biopharma, issues Series C Preferred, raises ~$43M in PIPE","bullets":["Acquired Cy Biopharma on Aug 5, 2026; Cy stockholders received 282,122 shares of Series C Preferred Stock (convertible 1:1,000 into common).","Raised ~$43M via PIPE: 120,260 Series C shares in two tranches; initial close Aug 7, 2026, milestone tranche subject to clinical trial.","Lynn Kirkpatrick resigned as President; James Morrison (founder of Cy) appointed President and director, to become CEO after stockholder vote.","Eliminated Series B Preferred Stock; all outstanding shares converted into 3,229,276 common shares; Certificate of Elimination filed.","Certain Cy stockholders and company insiders subject to 180-day lock-up on shares received in the merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-036268","json":"https://secwatch.observer/filing/0001493152-26-036268.json","markdown":"https://secwatch.observer/filing/0001493152-26-036268.md","text":"https://secwatch.observer/filing/0001493152-26-036268.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226036268/0001493152-26-036268-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226036268/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:25:18.515013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"606d91336a","claim":"James Morrison was appointed as Director at Ensysce Biosciences, Inc..","evidence_excerpt":"the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed James Morrison as President and as a director of the Company effective immediately upon the Closing","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226036268/0001493152-26-036268-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6de7b5736a","claim":"James Morrison was appointed as Chief Executive Officer at Ensysce Biosciences, Inc..","evidence_excerpt":"appointed Mr. Morrison as Chief Executive Officer effective upon approval of the Meeting Proposals.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226036268/0001493152-26-036268-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"8e07d17206","claim":"James Morrison was appointed as President at Ensysce Biosciences, Inc..","evidence_excerpt":"the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed James Morrison as President and as a director of the Company effective immediately upon the Closing","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226036268/0001493152-26-036268-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"92ca5bcb72","claim":"Lynn Kirkpatrick resigned as President at Ensysce Biosciences, Inc..","evidence_excerpt":"on August 5, 2026, Lynn Kirkpatrick resigned from her position as President of the Company, effective immediately upon the Closing.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226036268/0001493152-26-036268-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}